Nectar Lifesciences to acquire 100% stake in Avensis Exports for ₹24.96 Lakh, shifts RTA
Nectar Lifesciences will acquire 100% of Avensis Exports Private Limited (AEPL) for ₹24.96 Lakh to enter the real estate business. The acquisition is expected to complete within one month. Additionally, the company is changing its RTA from KFin Technologies to Alankit Assignments to improve efficiency and investor services.
The acquisition of a real estate entity, while a diversification, is a small financial transaction. The change in RTA is a routine operational update. The overall impact is moderate.
The company is diversifying into a new business vertical (real estate) through acquisition and also optimizing operational efficiency by changing the RTA, which are positive steps for future growth and cost savings.
Nectar Lifesciences Limited announced that its Board of Directors, in a meeting held on March 02, 2026, approved the acquisition of 100% paid-up equity share capital of Avensis Exports Private Limited (AEPL).
AEPL is engaged in the real estate business and has an incorporation date of October 16, 2007. The company has a paid-up equity share capital of ₹8,00,000 and a turnover of NIL for the last three financial years (2022-23, 2023-24, and 2024-25). The acquisition, which is not a related party transaction, is expected to help Nectar Lifesciences enter and diversify into the real estate business. The cost of acquisition is ₹24,96,000, representing 80,000 equity shares at ₹31.20 per share. The acquisition is expected to be completed within one month.
Furthermore, the Board also approved a change in the Company's Registrar and Share Transfer Agent (RTA) from M/s. KFin Technologies Limited (KFIN) to M/s. Alankit Assignments Limited (AAL). This change is aimed at reducing service costs, enhancing operational efficiency, and improving investor service experience. KFIN will continue as the RTA until data transition and other related procedures are completed. The effective date for the RTA change will be intimated in due course.
What to do with a filing like this
Nectar Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nectar Lifesciences Limited. Read the original for the full detail.